Valdecoxib
- Generic Name
- Valdecoxib
- Brand Names
- Bextra
- Drug Type
- Small Molecule
- Chemical Formula
- C16H14N2O3S
- CAS Number
- 181695-72-7
- Unique Ingredient Identifier
- 2919279Q3W
- Background
Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.
- Indication
For the treatment of osteoarthritis and dysmenorrhoea
- Associated Conditions
- Osteoarthritis (OA), Primary Dysmenorrhoea, Rheumatoid Arthritis
- Associated Therapies
- -
Analgesic Efficacy And Safety of Valdecoxib For Treatment Of Post-Surgical Pain From Bunionectomy Surgery
- First Posted Date
- 2008-05-23
- Last Posted Date
- 2008-05-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 450
- Registration Number
- NCT00683137
- Locations
- 🇺🇸
Pfizer Investigational Site, Tacoma, Washington, United States
A Multi-Center, Randomized, Double-Blind, Parallel Group Study To Compare The Efficacy And Tolerability Of Valdecoxib And Diclofenac In Patients With A Sprained Ankle
- Conditions
- Interventions
- First Posted Date
- 2008-05-05
- Last Posted Date
- 2008-05-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 202
- Registration Number
- NCT00671320
- Locations
- 🇵🇪
Pfizer Investigational Site, Lima, Peru
A Randomized, Double-Blind Study of the Efficacy and Safety of Valdecoxib Compared to Placebo for Treatment of Post- Cholecystectomy Surgery Pain
- Conditions
- Interventions
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2008-04-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 490
- Registration Number
- NCT00661635
- Locations
- 🇺🇸
Pfizer Investigational Site, Madison, Wisconsin, United States
A Double-blind, Double-dummy, Multicenter, Randomized Study of the Efficacy and Tolerability of Valdecoxib 40 mg Versus Rofecoxib 50 mg in Treating the Symptoms of Ankle Sprain
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2018-11-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 45
- Registration Number
- NCT00657449
- Locations
- 🇧🇷
Instituto Ortopedico de Goiania, Goiania, Goias, Brazil
🇧🇷Grupo Hospitalar Conceiçao, Porto Alegre, RS, Brazil
🇧🇷Hospital Geral do Grajau, São Paulo, SP, Brazil
Analgesic Efficacy Of Valdecoxib In Patients Following Bunion Surgery
- Conditions
- Interventions
- First Posted Date
- 2008-04-04
- Last Posted Date
- 2018-12-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 360
- Registration Number
- NCT00653354
- Locations
- 🇺🇸
Pfizer Investigational Site, Salt Lake City, Utah, United States
Double-Blind, Double Dummy, Randomized Comparison Study to Evaluate the Efficacy and Safety of Valdecoxib 10 mg Once Daily and Naproxen 500 mg Twice Daily in Treating the Signs and Symptoms of Osteoarthritis of the Knee
- First Posted Date
- 2008-04-04
- Last Posted Date
- 2008-04-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 265
- Registration Number
- NCT00652808
- Locations
- 🇰🇷
Pfizer Investigational Site, Seoul, Korea, Republic of
A Dose-Ranging Study Of Valdecoxib 5 Mg, 10 Mg, And 20 Mg Once Daily Versus Placebo In Patients With Osteoarthritis Of The Knee (Japan)
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2018-12-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 416
- Registration Number
- NCT00650624
- Locations
- 🇯🇵
Pfizer Investigational Site, Tokyo, Japan
A Multicentre, Double-Blind, Double-Dummy, Randomised Study of the Analgesic Efficacy and Safety of Valdecoxib Compared to Diclofenac Sodium in Patients Undergoing Knee Arthroscopy for Anterior Cruciate Ligament (ACL) Reconstruction
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2008-10-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 328
- Registration Number
- NCT00650598
- Locations
Pfizer Investigational Site
A Double Blind, Double Dummy, Randomized, Comparative Study Of The Efficacy And Safety Of Valdecoxib 40 Mg Twice Daily, As Needed In The First Menstrual Cycle Day And Then Once A Day, And Piroxicam 40 Mg Once A Day In The Treatment Of Patients With Primary Dysmenorrhea
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2018-12-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 154
- Registration Number
- NCT00649415
- Locations
- 🇧🇷
Pfizer Investigational Site, São Paulo, Brazil
A Double-Blind, Double Dummy, Randomized Comparison Study Of The Efficacy And Safety Of Valdecoxib 10mg Once Daily And Naproxen 500mg Twice Daily In Treating The Signs And Symptoms Of Osteoarthritis Of The Knee Or Hip In Taiwan
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2018-12-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 130
- Registration Number
- NCT00648258
- Locations
- 🇨🇳
Pfizer Investigational Site, Taipei, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.